The Carcinoid Neuroendocrine Tumor Society (CNETS) India was established in 2013 by a group of healthcare professionals dedicated to advancing the field of neuroendocrine tumor (NET) disease management.
We have both professional and patient advocacy wings to connect with both NET specialists as well as to support patients in the Indian subcontinent.
What are Neuroendocrine Tumors
Neuroendocrine neoplasms (previously also known as “Carcinoid”, or “cancer-like”), are an uncommon group of cancers with an increasing incidence and prevalence worldwide. These cancers can arise at any location in the body where the Neuroendocrine cells exist.
Patients with Neuroendocrine Tumors (or NETs) often struggle with issues related to disease awareness, timely diagnosis and access to appropriate multidisciplinary care and support.
CNETS India is the first and only active patient advocacy group serving Neuroendocrine/Phaeochromocytoma/Paraganglioma patients in the Indian Subcontinent. Our aim is to increase awareness about NETs amongst the general public and healthcare professionals in South East Asian region and support all NET patients and caregivers in their journey with Neuroendocrine cancers.
Availability of Gallium 68 DOTANOC PET CT in India
Click on the map for an expanded view.
For more discussions and information on medical specialists, hospitals and availability of PRRT and other treatments for NETs in India, join our support group on Facebook- click here.
COVID 19 Resources
Novel Coronavirus or COVID -19 pandemic has affected the entire world. We’re sharing here some authentic sources of information and updates for our cancer patients, meant to help you, as well as your family and caregivers, better understand the impact of the COVID-19 pandemic on your cancer care.
Indian Government’s official page for all COVID 19 related updates can be accessed here
Advice for the Public from the World Health Organization (WHO) available here.
Guidelines for Cancer Patients from European Society of Medical Oncology can be accessed here.
Follow us on Facebook
Reach out to Us
Follow us on twitter here